Register a trial

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03758443




Registration number
NCT03758443
Ethics application status
Date submitted
19/11/2018
Date registered
29/11/2018

Titles & IDs
Public title
Efficacy & Safety of TD-1473 in Ulcerative Colitis
Scientific title
A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With TD-1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis
Secondary ID [1] 0 0
2018-002136-24
Secondary ID [2] 0 0
0157
Universal Trial Number (UTN)
Trial acronym
RHEA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ulcerative Colitis (UC) 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - TD-1473 Dose A
Treatment: Drugs - TD-1473 Dose B
Treatment: Drugs - TD-1473 Dose C
Treatment: Drugs - Placebo

Experimental: Active Treatment TD-1473 Dose A - Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.

Experimental: Active Treatment TD-1473 Dose B - Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.

Experimental: Active Treatment TD-1473 Dose C - Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.

Placebo comparator: Placebo - Participants will be randomized to receive an oral daily dose of placebo. Participants who received Placebo (and were non-responders) may move to an extended induction. Subjects who are on placebo will be assigned to active TD-1473 for the extended induction (they will be blinded to dose).


Treatment: Drugs: TD-1473 Dose A
See Arm description

Treatment: Drugs: TD-1473 Dose B
See Arm description

Treatment: Drugs: TD-1473 Dose C
See Arm description

Treatment: Drugs: Placebo
See Arm description
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Total Mayo Score (tMS) at Week 8
Timepoint [1] 0 0
Baseline to Week 8
Primary outcome [2] 0 0
Phase 3 Maintenance: Number of Participants Who Demonstrated Clinical Remission by Adapted Mayo Score Components at Maintenance Week (mWeek) 44
Timepoint [2] 0 0
mWeek 44
Secondary outcome [1] 0 0
Number of Participants Who Demonstrated Clinical Remission by Adapted Mayo Score Components at Week 8
Timepoint [1] 0 0
Week 8
Secondary outcome [2] 0 0
Phase 3 Maintenance: Number of Participants Who Demonstrated a Clinical Response by Adapted Mayo Score Components at mWeek 44
Timepoint [2] 0 0
Baseline to mWeek 44
Secondary outcome [3] 0 0
Phase 3 Maintenance: Number of Participants Who Demonstrated Endoscopic Remission by Adapted Mayo Score Components at mWeek 44
Timepoint [3] 0 0
mWeek 44
Secondary outcome [4] 0 0
Phase 3 Maintenance: Number of Participants Who Demonstrated Symptomatic Remission by Adapted Mayo Score Components at mWeek 44
Timepoint [4] 0 0
mWeek 44

Eligibility
Key inclusion criteria
* Is at least 18 years of age at screening
* Has a history of UC for at least 3 months prior to screening
* Has moderately-to-severely active UC, as defined by a Mayo endoscopic subscore of =2 points and an adapted Mayo score between 4 - 9 points inclusive
* Is corticosteroid-dependent or has demonstrated inadequate response, or intolerance to conventional therapy (aminosalicylates, corticosteroids, immunomodulators) or biologics
* Willing to use highly-effective methods of contraception during the study and for 7 days after the last dose
* Additional inclusion criteria apply
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Has symptoms suggestive of fulminant colitis, megacolon or intestinal perforation
* Likely to require surgery for UC or other major surgeries
* Has previously received / is currently receiving prohibited medications within specified timeframe
* Is refractory to 3 biologics with =2 mechanisms of action
* Has a current bacterial, parasitic, fungal, or viral infection
* Has clinically significant abnormalities in laboratory evaluations
* Has had any prior exposure to an approved Janus kinase (JAK) inhibitor or potential exposure to an investigational JAK inhibitor that was stopped due to intolerance or lack of efficacy
* Additional exclusion criteria apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/03/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
20/10/2021
Sample size
Target
Accrual to date
Final
239
Recruitment in Australia
Recruitment state(s)
QLD,VIC,WA
Recruitment hospital [1] 0 0
Theravance Biopharma Investigational Site - South Brisbane
Recruitment hospital [2] 0 0
Theravance Biopharma Investigational Site - Woolloongabba
Recruitment hospital [3] 0 0
Theravance Biopharma Investigational Site - Malvern
Recruitment hospital [4] 0 0
Theravance Biopharma Investigational Site - Murdoch
Recruitment postcode(s) [1] 0 0
4101 - South Brisbane
Recruitment postcode(s) [2] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [3] 0 0
3144 - Malvern
Recruitment postcode(s) [4] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Idaho
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Kentucky
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nevada
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
South Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Tennessee
Country [19] 0 0
United States of America
State/province [19] 0 0
Texas
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Sofiya
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Pleven
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Plovdiv
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Ruse
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Sliven
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Sofia
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Stara Zagora
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Veliko Tarnovo
Country [28] 0 0
Canada
State/province [28] 0 0
Ontario
Country [29] 0 0
France
State/province [29] 0 0
Champagne-ardenne
Country [30] 0 0
France
State/province [30] 0 0
Languedoc-roussillon
Country [31] 0 0
France
State/province [31] 0 0
Limousin
Country [32] 0 0
France
State/province [32] 0 0
Midi-pyrenees
Country [33] 0 0
France
State/province [33] 0 0
NORD Pas-de-calais
Country [34] 0 0
France
State/province [34] 0 0
PAYS DE LA Loire
Country [35] 0 0
France
State/province [35] 0 0
Picardie
Country [36] 0 0
France
State/province [36] 0 0
Rhone-alpes
Country [37] 0 0
Georgia
State/province [37] 0 0
Batumi
Country [38] 0 0
Georgia
State/province [38] 0 0
Tbilisi
Country [39] 0 0
Germany
State/province [39] 0 0
Baden-wuerttemberg
Country [40] 0 0
Germany
State/province [40] 0 0
Schleswig-holstein
Country [41] 0 0
Germany
State/province [41] 0 0
Thuringen
Country [42] 0 0
Germany
State/province [42] 0 0
Berlin
Country [43] 0 0
Greece
State/province [43] 0 0
Attica
Country [44] 0 0
Greece
State/province [44] 0 0
Crete
Country [45] 0 0
Greece
State/province [45] 0 0
Peloponnese
Country [46] 0 0
Hungary
State/province [46] 0 0
Fejer
Country [47] 0 0
Hungary
State/province [47] 0 0
Hajdu-bihar
Country [48] 0 0
Hungary
State/province [48] 0 0
Tolna
Country [49] 0 0
Hungary
State/province [49] 0 0
Budapest
Country [50] 0 0
Israel
State/province [50] 0 0
Rehoboth
Country [51] 0 0
Israel
State/province [51] 0 0
Haifa
Country [52] 0 0
Israel
State/province [52] 0 0
Holon
Country [53] 0 0
Israel
State/province [53] 0 0
Jerusalem
Country [54] 0 0
Israel
State/province [54] 0 0
Nahariya
Country [55] 0 0
Israel
State/province [55] 0 0
Petah Tikva
Country [56] 0 0
Israel
State/province [56] 0 0
Rehovot
Country [57] 0 0
Italy
State/province [57] 0 0
Milano
Country [58] 0 0
Italy
State/province [58] 0 0
Catanzaro
Country [59] 0 0
Italy
State/province [59] 0 0
Pavia
Country [60] 0 0
Japan
State/province [60] 0 0
Aichi
Country [61] 0 0
Japan
State/province [61] 0 0
Chiba
Country [62] 0 0
Japan
State/province [62] 0 0
Fukuoka
Country [63] 0 0
Japan
State/province [63] 0 0
Gifu
Country [64] 0 0
Japan
State/province [64] 0 0
Gunma
Country [65] 0 0
Japan
State/province [65] 0 0
Hiroshima-ken
Country [66] 0 0
Japan
State/province [66] 0 0
Hiroshima
Country [67] 0 0
Japan
State/province [67] 0 0
Kanagawa
Country [68] 0 0
Japan
State/province [68] 0 0
Miyagi
Country [69] 0 0
Japan
State/province [69] 0 0
Nagano
Country [70] 0 0
Japan
State/province [70] 0 0
Oita
Country [71] 0 0
Japan
State/province [71] 0 0
Osaka Fu
Country [72] 0 0
Japan
State/province [72] 0 0
Osaka
Country [73] 0 0
Japan
State/province [73] 0 0
Saitama Ken
Country [74] 0 0
Japan
State/province [74] 0 0
Saitama
Country [75] 0 0
Japan
State/province [75] 0 0
Toyama
Country [76] 0 0
Japan
State/province [76] 0 0
Kumamoto
Country [77] 0 0
Japan
State/province [77] 0 0
Tokyo
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Gangwon-do
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Gyeonggi-do
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Daegu
Country [81] 0 0
Korea, Republic of
State/province [81] 0 0
Seoul
Country [82] 0 0
Poland
State/province [82] 0 0
Dolnoslaskie
Country [83] 0 0
Poland
State/province [83] 0 0
Kujawsko-Pomorskie
Country [84] 0 0
Poland
State/province [84] 0 0
Lodzkie
Country [85] 0 0
Poland
State/province [85] 0 0
Lodzki
Country [86] 0 0
Poland
State/province [86] 0 0
Malopolskie
Country [87] 0 0
Poland
State/province [87] 0 0
Mazowieckie
Country [88] 0 0
Poland
State/province [88] 0 0
Pomorskie
Country [89] 0 0
Poland
State/province [89] 0 0
Slaskie
Country [90] 0 0
Poland
State/province [90] 0 0
Swietokrzyskie
Country [91] 0 0
Poland
State/province [91] 0 0
Wielkopolskie
Country [92] 0 0
Poland
State/province [92] 0 0
Zachodniopomorskie
Country [93] 0 0
Poland
State/province [93] 0 0
Szczecin
Country [94] 0 0
Portugal
State/province [94] 0 0
Coimbra
Country [95] 0 0
Portugal
State/province [95] 0 0
Guimarães
Country [96] 0 0
Portugal
State/province [96] 0 0
Leiria
Country [97] 0 0
Portugal
State/province [97] 0 0
Lisboa
Country [98] 0 0
Portugal
State/province [98] 0 0
Santa Maria Da Feira
Country [99] 0 0
Portugal
State/province [99] 0 0
Senhora da Hora
Country [100] 0 0
Portugal
State/province [100] 0 0
Viana Do Castelo
Country [101] 0 0
Portugal
State/province [101] 0 0
Vila Nova De Gaia
Country [102] 0 0
Romania
State/province [102] 0 0
Timis
Country [103] 0 0
Romania
State/province [103] 0 0
Bucuresti
Country [104] 0 0
Serbia
State/province [104] 0 0
Belgrade
Country [105] 0 0
Serbia
State/province [105] 0 0
Kragujevac
Country [106] 0 0
Serbia
State/province [106] 0 0
Nis
Country [107] 0 0
Serbia
State/province [107] 0 0
Subotica
Country [108] 0 0
Serbia
State/province [108] 0 0
Zrenjanin
Country [109] 0 0
Slovakia
State/province [109] 0 0
Prešovsky
Country [110] 0 0
Slovakia
State/province [110] 0 0
Nitra
Country [111] 0 0
Slovakia
State/province [111] 0 0
Šahy
Country [112] 0 0
South Africa
State/province [112] 0 0
Gauteng
Country [113] 0 0
Spain
State/province [113] 0 0
Barcelona
Country [114] 0 0
Spain
State/province [114] 0 0
Madrid
Country [115] 0 0
Spain
State/province [115] 0 0
Sevilla
Country [116] 0 0
Spain
State/province [116] 0 0
Valencia
Country [117] 0 0
Taiwan
State/province [117] 0 0
Kaohsiung
Country [118] 0 0
Taiwan
State/province [118] 0 0
Taichung
Country [119] 0 0
Taiwan
State/province [119] 0 0
Tainan
Country [120] 0 0
Taiwan
State/province [120] 0 0
Taipei
Country [121] 0 0
Ukraine
State/province [121] 0 0
Kiev City
Country [122] 0 0
Ukraine
State/province [122] 0 0
Kiev
Country [123] 0 0
Ukraine
State/province [123] 0 0
Poltava
Country [124] 0 0
Ukraine
State/province [124] 0 0
Transcarpathian
Country [125] 0 0
Ukraine
State/province [125] 0 0
Vinnytsya
Country [126] 0 0
Ukraine
State/province [126] 0 0
Chernivtsi
Country [127] 0 0
Ukraine
State/province [127] 0 0
Kharkiv
Country [128] 0 0
Ukraine
State/province [128] 0 0
Lviv
Country [129] 0 0
Ukraine
State/province [129] 0 0
Ternopil
Country [130] 0 0
Ukraine
State/province [130] 0 0
Vinnytsia
Country [131] 0 0
Ukraine
State/province [131] 0 0
Zaporizhzhya
Country [132] 0 0
Ukraine
State/province [132] 0 0
Úzhgorod

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Theravance Biopharma
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Monitor
Address 0 0
Theravance Biopharma
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results are available at https://clinicaltrials.gov/study/NCT03758443